Research on the effect of formononetin on photodynamic therapy 
in K562 cells

Lü, Yao; Zhang, Sujuan; Wang, Kaige; Sun, Zhe

doi:10.4149/gpb_2017004

Cited by 5 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Formononetin (Figure 12), is an isoflavone, isolated from the roots of Trifolium pratense, Astragalus membranaceus, Glycyrrhiza glabra, or Pueraria lobate [321]. It has the ability to influence a number of carcinogenesis pathways in different malignant cells through various molecular mechanisms [322][323][324][325][326]. Formononetin has various pharmacological activities, such as anti-inflammatory, antiviral, antioxidant, neuroprotective activity, and wound healing [325,[327][328][329][330].…”

Section: Formononetinmentioning

confidence: 99%

Bioactive Compounds from Herbal Medicine Targeting Multiple Myeloma

et al. 2021

View full text Add to dashboard Cite

Multiple myeloma (MM) is one of the most widespread hematological cancers. It is characterized by a clonal proliferation of malignant plasma cells in the bone marrow and by the overproduction of monoclonal proteins. In recent years, the survival rate of patients with multiple myeloma has increased significantly due to the use of transplanted stem cells and of the new therapeutic agents that have significantly increased the survival rate, but it still cannot be completely cured and therefore the development of new therapeutic products is needed. Moreover, many patients have various side effects and face the development of drug resistance to current therapies. The purpose of this review is to highlight the bioactive active compounds (flavonoids) and herbal extracts which target dysregulated signaling pathway in MM, assessed by in vitro and in vivo experiments or clinical studies, in order to explore their healing potential targeting multiple myeloma. Mechanistically, they demonstrated the ability to promote cell cycle blockage and apoptosis or autophagy in cancer cells, as well as inhibition of proliferation/migration/tumor progression, inhibition of angiogenesis in the tumor vascular network. Current research provides valuable new information about the ability of flavonoids to enhance the apoptotic effects of antineoplastic drugs, thus providing viable therapeutic options based on combining conventional and non-conventional therapies in MM therapeutic protocols.

show abstract

Section: Formononetinmentioning

confidence: 99%

Bioactive Compounds from Herbal Medicine Targeting Multiple Myeloma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The identification and development of small molecules from existing natural sources can be an effective approach for therapeutically targeting various malignancies, including myeloma [36,37]. Formononetin (7-hydroxy-3-(4-methoxyphenyl)chromen-4-one) (FT), an isoflavone, predominantly isolated from the roots of Astragalus membranaceus , Trifolium pratense , Glycyrrhiza glabra , and Pueraria lobate can affect various important hallmarks of cancer in different malignant cells by diverse molecular mechanism(s) [38,39,40,41,42,43]. It can display numerous pharmacological properties, including anti-inflammatory, antioxidant, antiviral and neuroprotective activity, and wound healing capability [38,44,45,46,47].…”

Section: Introductionmentioning

confidence: 99%

Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model

Chulwon

Lee

et al. 2019

Biomolecules

View full text Add to dashboard Cite

Here, we determined the anti-neoplastic actions of formononetin (FT) against multiple myeloma (MM) and elucidated its possible mode of action. It was observed that FT enhanced the apoptosis caused by bortezomib (Bor) and mitigated proliferation in MM cells, and these events are regulated by nuclear factor-κB (NF-κB), phosphatidylinositol 3-kinase (PI3K)/AKT, and activator protein-1 (AP-1) activation. We further noted that FT treatment reduced the levels of diverse tumorigenic proteins involved in myeloma progression and survival. Interestingly, we observed that FT also blocked persistent NF-κB, PI3K/AKT, and AP-1 activation in myeloma cells. FT suppressed the activation of these oncogenic cascades by affecting a number of signaling molecules involved in their cellular regulation. In addition, FT augmented tumor growth-inhibitory potential of Bor in MM preclinical mouse model. Thus, FT can be employed with proteasomal inhibitors for myeloma therapy by regulating the activation of diverse oncogenic transcription factors involved in myeloma growth.

show abstract